Quarry LP Boosts Stake in Insulet Co. (NASDAQ:PODD)

Quarry LP lifted its holdings in shares of Insulet Co. (NASDAQ:PODD) by 26.4% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 354 shares of the medical instruments supplier’s stock after acquiring an additional 74 shares during the quarter. Quarry LP’s holdings in Insulet were worth $82,000 as of its most recent filing with the SEC.

A number of other large investors also recently bought and sold shares of the company. Blue Trust Inc. raised its stake in Insulet by 84.1% during the third quarter. Blue Trust Inc. now owns 127 shares of the medical instruments supplier’s stock worth $30,000 after acquiring an additional 58 shares during the period. International Assets Investment Management LLC bought a new position in shares of Insulet during the second quarter valued at approximately $32,000. Venturi Wealth Management LLC raised its position in shares of Insulet by 633.3% during the 3rd quarter. Venturi Wealth Management LLC now owns 154 shares of the medical instruments supplier’s stock worth $36,000 after purchasing an additional 133 shares during the period. UMB Bank n.a. lifted its holdings in shares of Insulet by 81.0% in the 2nd quarter. UMB Bank n.a. now owns 181 shares of the medical instruments supplier’s stock worth $37,000 after purchasing an additional 81 shares during the last quarter. Finally, 1620 Investment Advisors Inc. bought a new position in Insulet during the 2nd quarter worth $52,000.

Insulet Stock Down 0.8 %

PODD opened at $265.46 on Monday. The stock’s fifty day moving average is $247.48 and its 200-day moving average is $217.32. Insulet Co. has a one year low of $160.19 and a one year high of $279.40. The company has a market capitalization of $18.62 billion, a PE ratio of 45.46, a P/E/G ratio of 4.12 and a beta of 1.21. The company has a debt-to-equity ratio of 1.21, a quick ratio of 2.80 and a current ratio of 3.68.

Analysts Set New Price Targets

A number of equities research analysts have issued reports on the company. Citigroup raised their target price on Insulet from $250.00 to $275.00 and gave the company a “buy” rating in a research note on Tuesday, October 1st. Sanford C. Bernstein initiated coverage on shares of Insulet in a research note on Wednesday, November 6th. They set an “outperform” rating and a $300.00 target price for the company. Canaccord Genuity Group upped their target price on shares of Insulet from $236.00 to $269.00 and gave the stock a “buy” rating in a research report on Wednesday, September 25th. Raymond James lifted their price target on Insulet from $213.00 to $260.00 and gave the company an “outperform” rating in a report on Monday, October 14th. Finally, Barclays increased their price objective on Insulet from $220.00 to $234.00 and gave the stock an “equal weight” rating in a report on Monday, November 11th. Three analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $253.27.

Insulet Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.